Clinical Trial

Boston University Announces Launch of SEQSTER’s 1-Click Records™ to Aid in Development of Early Alzheimer’s Screening Tool

The system will allow researchers to retrieve a person’s longitudinal health record in seconds. DxA-Funded Researcher and Goodes Prize Winner…

1 year ago

Boston University Announces Launch of SEQSTER’s 1-Click Records™ to Aid in Development of Early Alzheimer’s Screening Tool

The system will allow researchers to retrieve a person’s longitudinal health record in seconds. DxA-Funded Researcher and Goodes Prize Winner…

1 year ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July…

1 year ago

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company…

1 year ago

Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA

Cannabix is developing alcohol and marijuana breathalyzer devices to give law enforcement and employers a tool to enhance public safetyVANCOUVER,…

1 year ago

Parexel Releases 2023 Environmental, Social and Governance Report

DURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the…

1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

1 year ago

Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit

HUNTSVILLE, July 29, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary…

1 year ago

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go…

1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory…

1 year ago